<DOC>
	<DOCNO>NCT01427920</DOCNO>
	<brief_summary>This trial conduct Asia , Europe South America . The aim trial confirm efficacy subject drive titration ( individually adjust ) biphasic insulin aspart 30 ( BIAsp 30 ) twice daily term glycaemic control assess change glycosylated haemoglobin ( HbA1c ) .</brief_summary>
	<brief_title>Comparison Biphasic Insulin Aspart 30 Individually Adjusted Subject Trial Physician , Both Combined With Metformin Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Diagnosed type 2 diabetes minimum 12 month prior Visit 1 ( screen ) Currently treat basal insulin analogue least 3 month prior Visit 1 ( screen ) Stable treatment ( change dose regimen ) total daily dose least 1500 mg metformin maximum tolerate dose ( minimum 1000 mg ) Â± additional OAD treatment . The metformin treatment must stable least 2 month prior Visit 1 ( screen ) HbA1c high equal 7.0 % equal 10.0 % ( one retest within one week screen visit allow . The last sample conclusive ) Body Mass Index ( BMI ) equal 40.0 kg/m^2 Able willing eat least 2 main meal day trial Able willing adhere protocol include compliance performance self measure plasma glucose ( SMPG ) , injection regimen titrate accord protocol Experience perform self measure plasma glucose ( SMPG ) Treatment thiazolidinedione ( TZD ) glucagonlike peptide1 ( GLP1 ) receptor agonist pramlintide within last 3 month prior Visit 1 ( screen ) Impaired hepatic function define alanine aminotransferase ( ALAT ) equal 2.5 time upper reference limit ( one retest within one week screen visit allow . The last sample conclusive ) Impaired kidney function serum creatinine equal 133 micromol/L ( 1.5 mg/dL ) males equal 124 micromol/L ( 1.4 mg/dL ) female ( one retest within one week screen visit allow . The last sample conclusive ) Cardiac problem uncontrolled treated/untreated severe hypertension ( define systolic blood pressure high equal 180 mmHg and/or diastolic blood pressure high equal 100 mmHg ) Previous use premixed insulin product ( premixed insulin analogue premixed human preparation ) bolus insulin . Previous use premixed bolus insulin product allow case hospitalisation severe condition require intermittent use premixed bolus insulin product less 14 consecutive day , last 3 month prior screen visit ( Visit 1 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>